COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Anecortave Acetate Versus Placebo in AMD Patients Following PDT

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00346866
Recruitment Status : Completed
First Posted : June 30, 2006
Last Update Posted : August 5, 2008
Information provided by:
Alcon Research

Brief Summary:
The purpose of this study was to evaluate the efficacy of anecortave acetate for depot suspension (30 mg and 15 mg) plus PDT versus PDT alone with respect to maintenance of visual acuity in patients with wet AMD.

Condition or disease Intervention/treatment Phase
AMD Drug: anecortave acetate Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 136 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Anecortave Acetate Versus Placebo in AMD Patients Following PDT
Study Start Date : May 2000
Actual Primary Completion Date : December 2001
Actual Study Completion Date : December 2001

Primary Outcome Measures :
  1. Mean change from the baseline in logMAR visual acuity score at Month 6

Secondary Outcome Measures :
  1. % patients who maintained vision, number of months of angiographic evidence of needing PDT re-treatment, and mean lesion sizes for the total choroidal neovascularization (CNV) and the classic component to the total CNV.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • AMD disease

Exclusion Criteria:

  • Age

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00346866

Layout table for location information
United States, Ohio
Beachwood, Ohio, United States, 44122
Sponsors and Collaborators
Alcon Research
Layout table for investigator information
Study Director: Patricia Zilliox Alcon Research
Layout table for additonal information Identifier: NCT00346866    
Other Study ID Numbers: C-00-07
First Posted: June 30, 2006    Key Record Dates
Last Update Posted: August 5, 2008
Last Verified: August 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents